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Abstract
Background: Breast cancer (BrCa) is a complex disease driven by aberrant gene alterations and environmental factors.
Recent studies reveal that abnormal epigenetic gene regulation also plays an important role in its pathogenesis. Ubiquitin
carboxyl- terminal esterase L1 (UCHL1) is a tumor suppressor silenced by promoter methylation in multiple cancers, but its
role and alterations in breast tumorigenesis remain unclear.
Methodology/Principal Findings: We found that UCHL1 was frequently downregulated or silenced in breast cancer cell
lines and tumor tissues, but readily expressed in normal breast tissues and mammary epithelial cells. Promoter methylation
of UCHL1 was detected in 9 of 10 breast cancer cell lines (90%) and 53 of 66 (80%) primary tumors, but rarely in normal
breast tissues, which was statistically correlated with advanced clinical stage and progesterone receptor status.
Pharmacologic demethylation reactivated UCHL1 expression along with concomitant promoter demethylation. Ectopic
expression of UCHL1 significantly suppressed the colony formation and proliferation of breast tumor cells, through inducing
G0/G1 cell cycle arrest and apoptosis. Subcellular localization study showed that UCHL1 increased cytoplasmic abundance
of p53. We further found that UCHL1 induced p53 accumulation and reduced MDM2 protein level, and subsequently
upregulated the expression of p21, as well as cleavage of caspase3 and PARP, but not in catalytic mutant UCHL1 C90S-
expressed cells.
Conclusions/Significance: UCHL1 exerts its tumor suppressive functions by inducing G0/G1cell cycle arrest and apoptosis in
breast tumorigenesis, requiring its deubiquitinase activity. Its frequent silencing by promoter CpG methylation may serve as
a potential tumor marker for breast cancer.
Citation: Xiang T, Li L, Yin X, Yuan C, Tan C, et al. (2012) The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53
and Is Frequently Silenced in Breast Cancer. PLoS ONE 7(1): e29783. doi:10.1371/journal.pone.0029783
Editor: Xin-yuan Guan, The University of Hong Kong, China
Received September 27, 2011; Accepted December 5, 2011; Published January 18, 2012
Copyright:  2012 Xiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Chongqing Health Bureau grant, National Natural Science Foundation of China (#31171243, 81072148 and 81172582)
and Shenzhen Science Fund for Distinguished Young Scholars (#JC201005270328A). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rgs726@163.com (GR); qtao@clo.cuhk.edu.hk (QT)
Introduction
Breast cancer has been the most common malignancy and the
major cause of cancer-related mortality of women worldwide [1].
Although there have been major improvement in the diagnosis
and treatment of breast cancer in recent years, early detection
methods for breast cancer are still limited. Abnormal promoter
methylation is the major mechanism for the inactivation of tumor
suppressor genes (TSGs) in tumorigenesis [2,3]. Increased
evidences have demonstrated that aberrant promoter methyla-
tion is a promising tumor marker for the early detection of
multiple malignancies including breast cancer [4,5,6]. Thus,
identification of more epigenetically-disrupted TSGs in breast
cancer is needed.
Protein ubiquitination plays a critical role in various biological
processes including cell proliferation, cell cycle, apoptosis, signal
transduction, while its deregulation contributes to tumor initiation
and progression [7,8]. Ubiquitin carboxyl- terminal esterase L1
(UCHL1), a dual-regulator of the ubiquitin proteasome pathway,
controls intracellular protein stability by transferring ubiquitin
directly to protein substrates and releasing ubiquitin from
tandemly conjugated ubiquitin monomers [9,10]. UCHL1 has
been identified as a cancer-specific methylated gene, and silenced
by promoter methylation in multiple tumors including nasopha-
ryngeal (NPC) [11,12], esophageal squamous cell (ESCC) [13,14],
gastric [15], hepatocellular (HCC) [15], colorectal [15], renal cell
[16], and ovarian carcinomas [17]. Our previous work have
identified that UCHL1 exerts tumor suppressor activities by
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inhibiting cell proliferation and inducing apoptosis of NPC, HCC
and other carcinoma cells [11,15]. However, the epigenetic
disruption of UCHL1 in breast tumorigenesis and its potential as
tumor marker remain ambiguous.
Here, we report that UCHL1 is frequently methylated in breast
cancer cell lines and primary tumors, but rarely in normal breast
tissues and mammary epithelial cells, well correlated with its
downregulation or silencing. Promoter methylation of UCHL1 is
significantly correlated with pathologic stage of breast cancer and
progesterone receptor status. Ectopic UCHL1 expression in breast
tumor cells suppresses cell growth, induces G0/G1 arrest and
apoptosis through disrupting p53 signaling, depending on its
deubiquitinase (DUB) activity, suggesting that UCHL1 is a
functional tumor suppressor and potential tumor marker for this
cancer.
Results
Reduced expression of UCHL1 in breast cancer
As both UCHL1 and USP10 increase p53 stability by
deubiquitination, we first examined the expression of UCHL1
and USP10 in normal human tissues including breast tissues, as
well as mammary epithelial and breast cancer cell lines, using RT-
PCR. UCHL1 expression was frequently downregulated or
silenced in breast cancer cell lines, but broadly expressed in all
the normal adult tissues and mammary epithelial cell lines (Fig. 1A
and B), while USP10 is widely expressed in both normal tissues and
breast cancer cell lines. Western blot confirmed UCHL1
expression in protein level in breast cancer cell lines, consistent
with mRNA level (Fig. 1C).
We further analyzed UCHL1 expression using a tissue
microarray carrying 30 breast cancer tissues and paired adjacent
non-cancerous tissues by immunohistochemistry. The immuno-
staining quantification of UCHL1 was analyzed by using Image
Pro-Plus (IPP) including 3 parameters: density mean, area sum,
and integrated optical density (IOD). Result showed that UCHL1
expression was significantly reduced in breast cancer tissues
compared to the adjacent noncancerous tissues (p,0.05) (Fig. 1D).
These results suggest that UCHL1 is frequently downregulated in
breast cancer.
Promoter methylation of UCHL1 and restoration of UCHL1
expression by demethylation
We next investigated whether promoter CpG methylation was
responsible for the silencing of UCHL1 in breast cancer. MSP
analysis showed that UCHL1 was frequently methylated in 9/10
(90%) breast cancer cell lines, well correlated with expression
levels, while no UCHL1 methylation was found in two normal
mammary epithelial cell lines (Fig. 2A).
We then treated methylated and silenced breast cell lines,
MB231, MB435 and T47D, with demethylation reagent 5-aza-29-
Figure 1. Downregulation of UCHL1 in breast cancer. (A and B) UCHL1 and USP10 expression in normal adult tissues (A), mammary epithelial
cell lines and breast cancer cell lines (B), were evaluated using semi-quantitative RT-PCR, with GAPDH as a control. (C) UCHL1 protein expression was
detected breast cancer cell lines by western blot. (D) Immunohistochemical analysis of UCHL1 in paired adjacent non-cancerous breast tissues and
primary breast tumors.
doi:10.1371/journal.pone.0029783.g001
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UCHL1expression wasdramaticallyrestored aftertreatment inthese
cell lines, together with increase in unmethylated alleles of the
UCHL1promoter(Fig.2B).These resultsdemonstratethat promoter
methylation of UCHL1 mediates its silencing in breast cancer.
UCHL1 methylation and its clinical correlation in breast
tumors
To address whether methylation occurs in primary tumors, we
analyzed the promoter methylation of UCHL1 in 66 breast tumor
samples, 20 breast tumor adjacent tissues, and 28 normal breast
tissues using MSP. UCHL1 promoter methylation was observed in
53 of 66 (80%) primary tumors, 3 of 20 (15%) adjacent normal
tissues and 1 of 28 (3.5%) normal breast tissues (Fig. 3, Table 1).
Detailed BGS analysis of representative samples further confirmed
the MSP data (Fig. 3D).
We further analyzed the correlation of UCHL1 methylation with
clinicopathological features (Table 2). UCHL1 methylation was
statistically correlated with clinical stage and progesterone receptor
(PR) status. However, there was no association of UCHL1
methylation with other clinicopathological characteristics of pa-
tients, including age, histological type, tumor size, lymph node
metastasis, oestrogen receptor (ER) and Hormone Receptor (HR)
status. These results indicate that promoter methylation of UCHL1
plays an important role in breast tumorigenesis and might be a
potential tumor marker for this cancer.
Ectopic UCHL1 expression inhibited colony formation
and proliferation of breast cancer cells
Silencing of UCHL1 by promoter methylation in breast cancer
indicated that UCHL1 might be a functional tumor suppressor in
breast tumorigenesis. We thus performed colony formation assay
of MB231 and MCF-7 cells which had complete methylation and
Figure 2. UCHL1 methylation in breast cancer cell lines and
reactivation of UCHL1 by demethylation. (A) UCHL1 is frequently
methylated in breast cancer cell lines. (B) Pharmacological demethyl-
ation restores UCHL1 expression. A+T: Aza and TSA treatment. M,
methylated; U, unmethylated.
doi:10.1371/journal.pone.0029783.g002
Figure 3. Promoter methylation of UCHL1 in primary breast tumors. (A, B, C) Representative analysis of UCHL1 methylation by MSP in normal
breast tissues, breast tumor adjacent tissues and primary tumors. M, methylated; U, unmethylated. (D) Detailed BGS analysis of UCHL1 promoter in
primary tumor and normal breast tissue. Circles, single CpG sites analyzed; row of circles, individual promoter allele cloned, randomly selected and
sequenced; Filled circle, methylated; empty circle, unmethylated.
doi:10.1371/journal.pone.0029783.g003
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suppressed the colony formation abilities of breast tumor cells,
compared with vector-transfected cells (down to ,20% and 70%,
respectively; Fig. 4). The effects of UCHL1 expression on cell
growth at 24, 48 and 72 hrs were also assessed by CCK-8 assay. In
UCHL1-expressing MB231 cells, cell growth was significantly
decreased at 48 h and 72 h (p,0.05) (Fig. 4D), but increased in
vector-expressing cells in a time-dependent manner. These data
suggest that UCHL1 suppresses cell proliferation of breast cancer.
UCHL1 induced G0/G1cell cycle arrest and apoptosis of
breast tumor cells
We further investigated the effects of UCHL1 on cell cycle and
apoptosis of breast cancer cells. Representative results of cell-cycle
Table 1. Methylation status of the UCHL1 promoter in
primary breast tumors.
Samples UCHL1 promoter Frequency of methylation
Methylated Unmethylated
BrCa (n=66) 53 13 53/66 (80%)
BA (n=20) 3 17 3/20 (15%)
BNP (n=28) 1 27 1/28 (3.5%)
Note: BrCa, breast cancer; BA, breast cancer adjacent tissues; BNP, breast normal
tissues.
doi:10.1371/journal.pone.0029783.t001
Table 2. Clinicopathological features and UCHL1 methylation of breast tumors.
Clinicopathological features Number UCHL1 methylation status p value
(n=66) Methylated Unmethylated
Age
#40 5 2 3 p=0.25-0.1
.40 31 24 7
unknown 30 23 7
Stage
I2 0 2 p,0.005
II 20 19 1
III 3 0 3
unknown 41 30 11
Histological type
Invasive ductal carcinoma 31 23 8 p=0.75-0.5
Invasive lobular carcinoma 2 2 0
unknown 33 25 8
Tumour size
,2.0 cm 18 12 6 p=0.75-0.5
$2.0 cm#5.0 cm 18 14 4
.5.0 cm 0 0 0
unknown 30 24 6
Lymph node metastasis
Positive 13 11 2 p=0.75-0.5
Negative 21 16 5
unknown 32 23 9
Oestrogen receptor (ER) status
Positive 18 12 6 p=0.75-0.5
Negative 13 11 2
unknown 35 26 9
Progesterone receptor (PR) status
Positive 14 8 6 p,0.005
Negative 16 11 2
unknown 30 31 9
Hormone Receptor (HR) status
Positive 13 9 4 p=0.9-0.75
Negative 17 13 4
unknown 36 27 9
doi:10.1371/journal.pone.0029783.t002
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shown in Figure 5A. Flow cytometry analysis revealed a
statistically significant increase in the number of UCHL1-
expressing cells with G0/G1phase (21% increase, p,0.05;
Fig. 5A) accompanied by the decrease of S and G2-M cells,
compared to control-transfected cells (Fig. 5B).
Next, we evaluated the apoptotic effect of UCHL1 in breast
cancer cells using TUNEL and annexin V-FITC/PI staining
assays. TUNEL assay showed that apoptosis was obviously
induced in UCHL1-transfected MB231 cells (Fig. 6A). Represen-
tative Annexin V-FITC staining was shown in Figure 6A. Similar
to that measured by the TUNEL assay, the percentage of Annexin
V-PI-positive cells was increased in UCHL1-transfected MB231
cells and reached 71.8%, compared with controls (Fig. 6B). These
results indicate that the inhibitory effect of cell proliferation by
UCHL1 is most likely mediated by G0/G1cell cycle arrest and
apoptosis.
Effect of UCHL1 on cell cycle and apoptosis is related to
p53 accumulation, requiring its deubiquitinase activity
As both growth arrest and apoptosis are associated with the
induction of p53, and UCHL1 has been identified increased p53
accumulation by deubiquitination, we firstly examined the
possible correlation between UCHL1 expression and p53
cytoplasmic localization. Immunostaining showed that UCHL1
is primarily located in cytoplasm as expected, and increased the
abundance of cytoplasmic p53 in UCHL1-expressing MB231
cells (Fig. 7A), but not in the controls (data not shown),
suggesting that UCHL1 contributes to cytoplasmic retention of
p53.
We then assessed the expression of p53 in UCHL1-expressed
MB231 cells, using its catalytic mutant UCHL1 C90S as a
control in addition to the vector only [10]. Western blot showed
that UCHL1 promoted p53 accumulation in breast tumor cells,
along with the reduction of MDM2, while UCHL1 C90S did not
increase p53 accumulation, but partly decreased the expression
of MDM2 (Fig. 7B). In MB231- expressing UCHL1 cells, p53
protein level was showed 9-fold or greater changes compared to
the controls, but no any change was observed in UCHL1 C90S-
expressing cells (Fig. 7C). We further found the expression of
p21 was dramatically increased in UCHL1-expressing cells,
which are the key G1/S cell cycle regulators and p53
downstream target genes, as well as cleaved-caspase 3 and
PARP (Fig. 7B), while little or no upregulation of these markers
was observed in UCHL1 C90S- expressing cells. Thus, upregu-
lated p53-signaling by UCHL1 through its DUB activity was
involved in G0/G1 cell cycle arrest and apoptosis in breast
cancer cells.
Figure 4. Effects of UCHL1 on the colony formation and cell proliferation of breast cancer cells. (A) Representative colony formation
assay. (B) Quantitative analysis of colony formation. The numbers of G418-resistant colonies in vector-transfected controls were set to 100%. Values
are expressed as mean6SD from three experiments, and the asterisks indicate statistical significance compared to controls (p,0.01). (C) Expression of
UCHL1 by RT-PCR in vector- and UCHL1-transfected MB231 and MCF-7 cells. (D) CCK-8 cell proliferation assay for vector- and UCHL1-transfecetd
MB231 cells. Asterisks indicate a significant level of proliferation compared to controls (p,0.05).
doi:10.1371/journal.pone.0029783.g004
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In the present study, we analyzed the epigenetic alteration of
UCHL1, its tumor suppressive functions and related-mechanisms
in breast cancer. We found that UCHL1 was abundantly expressed
in normal breast tissues and normal mammary epithelial cell lines,
but frequently downregulated or silenced in breast cancer cell lines
and primary tumors due to its promoter methylation, indicating
that aberrant promoter methylation is a major cause for UCHL1
disruption in breast cancer. In primary tumors, UCHL1 methyl-
ation was associated with clinical stage and progesterone receptor
status, indicating its potential as tumor marker for this cancer.
Functionally, ectopic expression of UCHL1 suppressed the colony
formation and cell proliferation of breast tumor cells through
inducing G0/G1cell cycle arrest and apoptosis. Furthermore, we
found that the p53 accumulation is mainly due to its cytoplasmic
retention by UCHL1, depending on its DUB activity, which is
responsible for the tumor suppressive function of UCHL1. Thus,
UCHL1, acts as a functional tumor suppressor by inhibiting cell
proliferation and inducing apoptosis, but is epigenetically-silenced
in breast cancer.
Abnormal of ubiquitin-proteasome signaling pathway is
closely associated with multiple tumorigenesis, including breast
cancer [8]. Malfunctions in the ubiquitin- proteasome system
enhance the effects of oncoproteins, reduce the protein levels of
tumor suppressor proteins, further leading to the inhibition of
apoptosis of tumor cells and promotion of cell proliferation [18].
UCHL1, located at 4p14, was first reported as a member of the
ubiquitin proteasome pathway [19], and plays an important role
in controlling intracellular ubiquitin levels in cells undergoing
ubiquitin-dependent protein degradation [9,20]. Promoter
methylation has been identified to be the major cause for
UCHL1 downregulation or silencing in multiple malignancies.
Although high expression of UCHL1 was reported to predict
early recurrence in patients with invasive breast cancer [21],
other evidences indicated the potential of UCHL1 as tumor
suppressor in breast cancer. Overexpression of UCHL1 has been
found to induce apoptosis in MCF-7 cells [22]. Using genomic
screening upregulated genes by demethylation agent treatment
in breast cancer cells, Fujikane et al found that UCHL1 was
methylated in primary breast tumors [23], consistent with our
studies.
Our previous work demonstrated that UCHL1 could activate
the p14ARF-p53 signaling pathway by deubiquitinating p53 and
p14ARF as well as ubiquitinating MDM2, which might be
through its two opposing enzyme activities, hydrolase and ligase,
further resulting in its tumor suppressive role in NPC tumorigen-
esis [11,15]. Although USP10 has been reported to regulate p53
localization and stability by deubiquitinating p53 directly [24], our
data showed that USP10, unlike UCHL1, is widely expressed in
both normal tissues and breast cancer cell lines, and no any
expression correlation in mRNA level between USP10 and UCHL1
was found in breast cancer, indicating UCHL1 is mainly
responsible for p53 stability in breast cancer.
Figure 5. Effect of UCHL1 on cell cycle distribution of MB231 cells. (A) Representative cell cycle analysis. (B) Summarized flow cytometry data.
Results are represented as average6S.D and are based on three independent experiments. Statistical significance was determined using Student’s t-
test (p,0.001).
doi:10.1371/journal.pone.0029783.g005
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ubiquitinase fucntion, and p53 is also reported to be localized in
cytoplasm in quiescent mammary gland without hormone
treatment, which is not responsible for p21 transcription [25].
Another report suggested that cytoplasmic p53 was usually wide
type and detected in normal breast tissue while mutated p53 is
located in nucleus in breast cancer tissues [26]. In this study, we
found that UCHL1 retained p53 in the cytoplasm substantially.
Furthermore, using catalytic mutant UCHL1 C90S as a control,
the accumulation of p53 mediated by UCHL1 was observed,
subsequently, p21, as key p53 downstream target genes and
regulators of cell cycle G1/S checkpoint, as well as cleaved-caspase
3 and PARP, were obviously upregulated, accompanied by
UCHL1-mediated p53 activation, but not in UCHL1 C90S-
expressing breast cancer cells. We also found a dramatic reduction
of MDM2 in UCHL1-expressing cells, but minor change was
observed in UCHL1 C90S-transfected cells, which is well correlated
with the function of UCHL1 C90S, lacking hydrolase activity but
maintaining binding affinity for ubiquitin. However, the study on
the mechanism of the negative correlation between UCHL1 and
MDM2 level needs to further investigated. Thus, ensuring proper
p53 signaling is tightly related to UCHL1-induced tumor
suppression in breast pathogenesis.
Recent studies have shown that UCHL1 methylation is
correlated with tumor cell differentiation, lymph node metastasis
and poor prognosis, thus as a tumor marker [12,13,23,27,28].
UCHL1 promoter methylation is an independent prognostic factor
for ESCC survival and thus a valuable tumor marker for ESCC
progression [13]. We also identified that UCHL1 methylation as a
biomarker for HCC and other digestive tumors previously [15]. In
breast cancer, we found that the promoter methylation of UCHL1
was a promising marker indicative of breast cancer progression.
In summary, we found that UCHL1 possesses tumor-suppres-
sive functions in breast tumor cells requiring its DUB activity, and
is frequently silenced by promoter methylation, thus as a potential
tumor marker for breast cancer. Our study further extends the
current understanding of the role of epigenetically-disrupted
tumor suppressor gene in breast tumorigenesis.
Materials and Methods
Cell lines and tumor samples
Ten breast tumor cell lines (BT549, MB435, MCF-7, T47D,
MDA-MB-231, MDA-MB-468, ZR75-1, SK-BR-3, YCC-B1 and
YYC-B3) were used [29,30]. Human normal mammary epithelial
cell lines HMEpC and HMEC (CA-830-05a, Applied Biosystems,
Foster City, CA) were used as controls. All cell lines were
maintained in RPMI 1640 (Gibco-BRL, Karlsruhe, Germany)
supplemented with 10% fetal bovine serum (FBS) (PAA Labora-
tories, Linz, Austria), 100 U/ml penicillin and 100 mg/ml
streptomycin, at 37uC in a humidified atmosphere containing
5% CO2 [29,30,31]. RNA samples of human normal adult tissues
were purchased commercially (Stratagene, La Jolla, CA; Millipore
Chemicon, Billerica, MA and BioChain Institute, Hayward, CA).
Figure 6. Detection of apoptosis induced by UCHL1 using TUNEL assay and Annexin V-FITC/PI staining in MB231 cells. (A) Apoptotic
cells detected by TUNEL staining. (B) Induction of apoptosis detected by flow cytometric analysis with Annexin V-FITC and PI-staining.
doi:10.1371/journal.pone.0029783.g006
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tissues have been described previously [32,33].
Some fresh breast tumors, adjacent non-cancerous tissues and
normal breast tissues were obtained from patients treated by
primary surgery at the First Affiliated Hospital Surgery Department
of Chongqing Medical University (Chongqing, China). All samples
were evaluated and subjected to histological diagnosis by expert
pathologists. Grading of tumors was achieved by staining with
hematoxylin and eosin (H&E). The clinical data, including race,
age, site of primary tumor, stage, receptor status and tumor
differentiation, were also obtained. All patients provided informed
consent for the study to retain and analyze their tissues for research
purposes. The samples were immediately snap-frozen following
resection and stored in liquid nitrogen until processing. The study
was approved by Institutional Review Board of the Chongqing
Medical University. The written informed consent was obtained.
DNA and RNA preparation
DNA and RNA were isolated as previously described [34,35].
Briefly, RNA was extracted using TRIzol reagent (Life Technol-
ogies Inc., Carlsbad, CA). DNA was extracted using Qiagen
DNeasy Tissue kit (Qiagen, Inc., Valencia, CA). Extracted DNA
and RNA were quantified using spectrophotometry analysis.
Samples were stored at 220uCo r280uC until use.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR of UCHL1 using Go-Taq (Promega,
Madison, WI) was performed as previously described with




RT-PCR was done with 32 cycles for UCHL1 and 23 cycles for
GAPDH.
Tissue microarray and immunohistochemistry
To evaluate the expression levels of UCHL1 protein in breast
cancer tissues, tissue microarray (TMA) was constructed using
paraffin-embedded, formalin-fixed tissues from 31 patients,
including primary tumor and adjacent tissues, and one pair as
positive controls (Biochip Co., Ltd., Shanghai, China). Immuno-
histochemistry was performed using UCHL1 polyclonal antibody
(ab10404, Abcam). Briefly, sections were deparaffinized, subjected
to microwave antigen retrieval for 15 min in sodium citrate
solution (pH 6.0) and then incubated with 3% hydrogen peroxide
to block endogenous peroxidase activity. The sections were
incubated with primary antibody (1:1000 dilution) overnight at
4uC, followed by second antibody (1:2000 dilution) at 37uC for one
hour. Finally, the slides were counterstained with hematoxylin.
Negative control was performed by replacing the primary
antibody with PBS.
Evaluation of UCHL1 expression by IPP (version 6.0, Media
Cybernetics, Silver Spring, MD) as described previously [36].
Briefly, 5 digital images at 136061024 pixel resolution at 400
magnification were captured by the LEICA DM500 ICC50
microscope (Leica microsystems, Germany).The measurement
parameters included density mean, area sum, and IOD. The optical
density was calibrated and the area of interest was set through: hue,
0,30; saturation, 0,255; intensity, 0,255, then the image was
converted to gray scale image, and the values were counted.
Figure 7. UCHL1 promotes the activation of p53 signaling depending on its deubiquitinase activity. (A) The subcellular localization of
UCHL1 and p53 was analyzed in UCHL1-transfected MB231 cells. (B) Western blot analysis of cell cycle- and apoptosis-related proteins in vector-,
UCHL1 and UCHL1 C90S-transfected MB231 cells. b-actin was used as a control. (C) Quantification of p53 protein expression by Western blot using
scanning and ImageJ software. Each sample was normalized to b-actin content.
doi:10.1371/journal.pone.0029783.g007
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sequencing (BGS)
Bisulfite modification of DNA, MSP and BGS were performed as
described previously [37,38]. The bisulfite-treated DNA was
amplified with the methylation-specific primer set UCHL1-m1: 59-
TTTATTTGGTCGCGATCGTTC ,UCHL1-m2: 59-AAACTA-
CATCTTCGCGAAACG or the unmethylation specific primer set
UCHL1-u1: 59-GGGTTTGTATTTATTTGGTTGT, UCHL1-
u2: 59-CTTAAACTACATCTTCACAAAACA. MSP was done
using AmpliTaq Gold (methylation-specific primers: annealing
temperature 60uC, 40 cycles; unmethylation- specific primers:
annealing temperature 58uC, 40 cycles).
For BGS, bisulfite-treated DNA was amplified using primers
UCHL1-BGS1: 59-GTTTTATATATTTAAGGAATATTT and
UCHL1-BGS2:
59-CTTAATCCCTACC AACAAC. The PCR products were
cloned into pCR4-Topo vector (Invitrogen, CA), with 8 to 10
colonies randomly chosen and sequenced.
Flow cytometry analysis of cell cycle and apoptosis
Flow cytometry analyses of cell cycle and apoptosis were
described previously [29,39]. For cell cycle analysis, cells were
fixed in ice-cold 70% ethanol and stained with propidium iodide
(PI). The cell-cycle profiles were assayed using the Elite ESP flow
cytometry at 488 nm, and the data were analyzed using the CELL
Quest software (BD Biosciences, San Jose, CA). For apoptosis
analysis, Annexin V-FITC/PI staining was also performed using
flow cytometry according to the manufacturer’s guidelines. Briefly,
cells were incubated with PI and Annexin V-fluorescein
isothiocynate in the darkness at room temperature. Flow
cytometric analysis was immediately performed.
Colony formation assay
For monolayer culture, freshly seeded tumor cells (2610
5/well)
were plated in a 6-well plate, cultured overnight, and transfected
with pcDNA3.1-UCHL1 or pcDNA3.1 plasmid using Lipofecta-
mine 2000 (Invitrogen, CA). Cells were plated in a new 6-well
plate 48 h post-transfection, and selected for 1–2 weeks using
G418 (1200 mg/ml), while untransfected cells would not survive
G418 selection. Surviving colonies ($50 cells per colony) were
counted after staining with Giemsa14 days post-transfection,
counted and photographed. Each experiment was run in triplicate,
and performed for three times.
Cell proliferation assay
For the analysis of cell growth rate, MB231 cells transfected as
above and plated in 96-well plate at a density of 5610
3 cells/well,
and cell proliferation assay was measured at 24, 48 and 72 h using
the Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technol-
ogies, Japan) according to the company’s instruction. Spectromet-
ric absorbance at 490 nm was measured using a microplate
reader. The data were obtained from three independent cultures
and each experiment was repeated four times.
TUNEL assay
Analysis of apoptotic cells was performed using the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) staining kit following the manufacturer’s instruction
(Roche, CA). Briefly, MB231 cells were grown on glass coverslips
and transfected with pcDNA3.1-UCHL1 or pcDNA3.1 plasmid
and cultured for 48 h. Transfected cells were then washed with
PBS, fixed with 4% paraformaldehyde in PBS, and incubated
with primary antibodies. The nuclei were counterstained with
DAPI (Roche, CA). TUNEL-positive cells had a pyknotic
nucleus with dark green fluorescent staining, indicative of
apoptosis. The TUNEL reaction was also visualized by
chromogenic staining with DAB (002114, Invitrogen, CA).
Images of the sections were taken using a fluorescence
microscope (Leica DM IRB).
Indirect Immunofluorescence
Cells grown on coverslips were stained by indirect immunoflu-
orescence as described previously [39]. Briefly, cells were
incubated with primary antibodies against UCHL1 and p53,
and then incubated with Alexa Fluor 555-(Invitrogen Molecular
Probes, Carlsbad, CA) or FITC-conjugated (Dako, Denmark)
secondary antibody against mouse or rabbit Ig G. Cells were then
counterstained with DAPI and imaged with a fluorescence
microscope (Leica DM IRB).
Construction of UCHL1 C90S expression vector
UCH L1 C90S mutant was introduced by PCR-based site-
directed mutagenesis (QuickChange Site-Directed Mutagenesis
Kit, Stratagene, La Jolla, CA, USA) of pcDNA3.1-UCHL1
plasmid using primers designed to introduce specific mutations
(C90S) and sequence verified.
Western blot
Western blot analysis was performed as described previously
[11]. The primary antibodies were used: UCHL1 (ab10404,
Abcam), cleaved caspase-3 (9661, Cell Signaling Technology,
Danvers, MA), cleaved PARP (9541,,Cell Signaling Technolo-
gy, Danvers, MA), p53 (sc-126, Santa Cruz, CA), MDM2 (sc-
813, Santa Cruz, CA), p21/Cip1 (2990-1, Epitomics, USA), and
b-catenin (1247-1, Epitomics, Burlingame, CA). p53 protein
level was determined and quantified by western blot using the
ImageJ.
Statistical analysis
Statistical analyses were performed using SPSS version 16
software. The expression analysis of UCHL1 between BrCa tissues
and the corresponding adjacent tissues were assessed using the
Student’s t-test. Comparisons of categorical variables were
performed using the x
2 test or 2-tailed t-test. Fisher’s exact test
was used when appropriate. Differences were considered statisti-
cally significant if a p value was less than 0.05.
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